PPARA and hyperlipidemia: While newer agents like Pemafibrate (approved in Japan for the treatment of hyperlipidemia) exhibit favorable safety profiles and hold therapeutic promise, their lack of approval in the U.S. highlights the need for the development of novel selective PPAR-α agonists [10,11].